This review explores challenges and advancements in car‐t therapy for solid tumors, suggesting improved treatments may emerge through innovative technologies and combination strategies.
Key Points
CAR‐T therapy shows potential for reshaping treatment in patients with solid tumors, as new strategies develop.
Recent trials in gastric cancer and glioma reveal promising clinical potential in enhancing car‐t efficacy.
Assessment of advancements like crispr editing and cytokine armoring aims to improve tumor specificity and T-cell persistence.
Ongoing research into combination strategies could further enhance the effectiveness of car‐t therapy, highlighting its impact on precision oncology.